- Alto Neuroscience to Present at the Jefferies Global Healthcare Conference
- Alto Neuroscience Appoints Michael Hanley as Chief Operating Officer
- Alto Neuroscience Reports First Quarter 2024 Financial Results and Recent Business Highlights
- Alto Neuroscience Announces Data Presentations Highlighting Late-Stage Clinical Pipeline and Robust Platform at Upcoming Scientific Conferences
- Alto Neuroscience Announces Positive Phase 1 Results for ALTO-101, a Novel PDE4 Inhibitor in Development for Schizophrenia
- Alto Neuroscience Announces Initiation of Phase 2 Study of ALTO-203 in Patients with Major Depressive Disorder
- Alto Neuroscience Reports Full Year 2023 Financial Results and Recent Business Highlights
- Alto Neuroscience Appoints Maha Radhakrishnan, M.D., to Board of Directors
More ▼
Key statistics
On Wednesday, Alto Neuroscience Inc (ANRO:NYQ) closed at 11.52, 6.18% above its 52-week low of 10.85, set on Jun 04, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 11.39 |
---|---|
High | 11.53 |
Low | 10.90 |
Bid | -- |
Offer | 16.00 |
Previous close | 11.31 |
Average volume | 117.40k |
---|---|
Shares outstanding | 26.88m |
Free float | 23.36m |
P/E (TTM) | -- |
Market cap | 321.53m USD |
EPS (TTM) | -1.90 USD |
Data delayed at least 15 minutes, as of Jun 06 2024 00:00 BST.
More ▼